Endocrine Pharmacology — MCQs

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 121: Which of the following is NOT a side effect of clomiphene citrate?

A. Multiple pregnancy
B. Increased risk of ovarian cancer
C. Multiple polycystic ovaries
D. Teratogenic effects on offspring (Correct Answer)

Explanation: **Explanation:** Clomiphene citrate is a **Selective Estrogen Receptor Modulator (SERM)** used as a first-line agent for ovulation induction in infertility. It acts by inhibiting the negative feedback of estrogen on the hypothalamus and pituitary, leading to an increase in GnRH, FSH, and LH levels, which stimulates follicular development. **Why Option D is correct:** Clomiphene citrate is **not known to be teratogenic**. While it is contraindicated during pregnancy (Pregnancy Category X), this is primarily because it has no therapeutic benefit once conception has occurred. Large-scale clinical studies have shown that the incidence of congenital anomalies in children born after clomiphene treatment is not significantly higher than in the general population. **Why the other options are incorrect:** * **A. Multiple pregnancy:** This is a common side effect (approx. 5-10%, mostly twins) because the rise in FSH often causes the maturation of more than one dominant follicle. * **B. Increased risk of ovarian cancer:** Long-term use (usually >12 cycles) has been epidemiologically linked to a slightly increased risk of borderline ovarian tumors, though this remains a subject of debate. * **C. Multiple polycystic ovaries:** Overstimulation can lead to the formation of multiple ovarian cysts and, in severe cases, Ovarian Hyperstimulation Syndrome (OHSS), although OHSS is less common with clomiphene than with gonadotropins. **NEET-PG High-Yield Pearls:** * **Mechanism:** Competitive antagonist of estrogen receptors in the hypothalamus. * **Site of Action:** Primarily the hypothalamus (blocks the "estrogen-sensing" mechanism). * **Common Side Effects:** Vasomotor flushes (hot flashes), breast tenderness, and visual disturbances (scotomas). * **Prerequisite:** A functional Hypothalamic-Pituitary-Ovarian (HPO) axis is required for it to work.

Question 122: What is the drug of choice for galactorrhea?

A. Bromocriptine
B. Cabergoline (Correct Answer)
C. Metformin
D. Dopamine

Explanation: **Explanation:** **Mechanism of Action:** Galactorrhea is most commonly caused by hyperprolactinemia. Prolactin secretion is under tonic inhibitory control by **Dopamine** (acting on D2 receptors in the pituitary). Therefore, **Dopamine Agonists** are the mainstay of treatment. **Why Cabergoline is the Correct Answer:** While both Bromocriptine and Cabergoline are D2 agonists, **Cabergoline** is currently the **Drug of Choice** for hyperprolactinemia and galactorrhea. It is preferred because: 1. **Higher Efficacy:** It is more effective in normalizing prolactin levels and shrinking prolactinomas. 2. **Better Tolerability:** It has significantly fewer gastrointestinal side effects (nausea/vomiting) compared to Bromocriptine. 3. **Longer Half-life:** It allows for convenient twice-weekly dosing, whereas Bromocriptine requires daily administration. **Analysis of Incorrect Options:** * **A. Bromocriptine:** Previously the drug of choice, it is now a second-line agent. It remains the preferred drug if pregnancy is desired (due to more extensive safety data), though Cabergoline is increasingly used here as well. * **C. Metformin:** An insulin sensitizer used in Type 2 Diabetes and PCOS; it has no role in treating galactorrhea. * **D. Dopamine:** While dopamine inhibits prolactin, it cannot be used as a drug for this condition because it does not cross the blood-brain barrier and has a very short half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Cabergoline** is a selective D2 agonist; **Bromocriptine** is a non-selective D2 agonist and D1 antagonist. * **Side Effects:** Ergot-derived agonists like Cabergoline can cause **cardiac valvulopathy** at high doses (rare in endocrine practice). * **Drug-Induced Galactorrhea:** Always rule out D2 antagonists like **Metoclopramide** or **Antipsychotics** (Haloperidol, Risperidone) as the underlying cause.

Question 123: Rapid infusion of insulin causes which of the following electrolyte imbalances?

A. Hyperkalemia
B. Hypokalemia (Correct Answer)
C. Hypernatremia
D. Hyponatremia

Explanation: **Explanation:** **Mechanism of Action (Why B is Correct):** Insulin plays a critical role in electrolyte homeostasis by stimulating the **Na⁺-K⁺ ATPase pump** located on the cell membranes of skeletal muscle and liver cells. When insulin levels rise rapidly (as in rapid infusion), it increases the activity of this pump, which pumps 3 Na⁺ ions out of the cell and **2 K⁺ ions into the cell**. This shift of potassium from the extracellular fluid (ECF) into the intracellular fluid (ICF) leads to a decrease in serum potassium levels, resulting in **Hypokalemia**. **Analysis of Incorrect Options:** * **A. Hyperkalemia:** This is the opposite of insulin’s effect. Hyperkalemia is often seen in insulin deficiency (e.g., Diabetic Ketoacidosis) because potassium shifts out of cells. * **C & D. Hypernatremia/Hyponatremia:** While insulin affects the Na⁺-K⁺ pump, its primary and most immediate clinical impact is on potassium. Insulin does not have a direct, significant effect on total body sodium levels that would typically manifest as acute hyper- or hyponatremia in this context. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Use:** Because insulin shifts potassium into cells, a combination of **Insulin + Glucose** (to prevent hypoglycemia) is a standard emergency treatment for **Hyperkalemia**. * **DKA Management:** In Diabetic Ketoacidosis (DKA), patients may have high serum potassium initially, but total body potassium is depleted. Starting insulin will cause a rapid drop in K⁺; therefore, **potassium supplementation** is often required even if initial serum levels appear normal. * **Other drugs causing Hypokalemia:** Beta-2 agonists (Salbutamol) and Diuretics (Thiazides/Loop).

Question 124: What is the only oral drug (among the given options) effective for the treatment of acromegaly?

A. Octreotide
B. Cabergoline (Correct Answer)
C. Pegvisomant
D. L-thyroxine

Explanation: **Explanation:** The treatment of acromegaly primarily involves surgery, but medical management is indicated when surgery is contraindicated or unsuccessful. **Why Cabergoline is correct:** **Cabergoline** is a long-acting **Dopamine (D2) agonist**. While dopamine normally stimulates growth hormone (GH) in healthy individuals, it paradoxically inhibits GH secretion from the pituitary somatotrophs in patients with acromegaly. Among the options provided, Cabergoline is the **only drug administered orally**. It is particularly effective in "mild" acromegaly or cases where there is co-secretion of Prolactin. **Analysis of Incorrect Options:** * **Octreotide (Option A):** A Somatostatin analog that is much more potent than natural somatostatin. However, it is a peptide and would be digested if taken orally; therefore, it must be administered via **subcutaneous or intramuscular** injection. * **Pegvisomant (Option C):** A **GH-receptor antagonist** that prevents GH from signaling at peripheral tissues. It is highly effective but must be administered via **daily subcutaneous injection**. * **L-thyroxine (Option D):** This is a synthetic T4 used for hypothyroidism. It has no therapeutic role in the management of acromegaly. **NEET-PG High-Yield Clinical Pearls:** 1. **Drug of Choice (DOC):** Transsphenoidal surgery is the first-line treatment. For medical management, **Somatostatin analogs (Octreotide/Lanreotide)** are the first-line drugs. 2. **Pegvisomant** is unique because it does not shrink the tumor; it only blocks the peripheral action of GH (lowers IGF-1). 3. **Pasireotide** is a newer somatostatin analog with a higher affinity for SSTR5, often used in resistant cases. 4. **Side Effects:** Octreotide commonly causes biliary sludge or gallstones due to inhibition of gallbladder contractility.

Question 125: Hypothyroidism should be treated with daily administration of which of the following thyroid hormone preparations?

A. Thyroid extract
B. Thyroglobulin
C. Thyroxine (T4) (Correct Answer)
D. Triiodothyronine (T3)

Explanation: **Explanation:** **Levothyroxine (T4)** is the drug of choice for the treatment of hypothyroidism because it mimics the physiological secretion of the thyroid gland. 1. **Why T4 is the Correct Choice:** * **Pharmacokinetics:** T4 has a long half-life (approx. 7 days), allowing for convenient **once-daily dosing** and stable serum levels. * **Physiological Conversion:** T4 acts as a pro-hormone. The body peripherally converts T4 into T3 (the active form) via deiodinase enzymes as per metabolic demand. This prevents the "peaks and valleys" in hormone levels associated with direct T3 administration. * **Safety:** It is well-tolerated, inexpensive, and easy to monitor using Serum TSH levels. 2. **Why Other Options are Incorrect:** * **Thyroid Extract & Thyroglobulin (Options A & B):** These are older, animal-derived preparations (e.g., desiccated porcine thyroid). They are no longer recommended because they contain unpredictable ratios of T3 and T4, leading to instability and potential allergic reactions to foreign proteins. * **Triiodothyronine (T3/Liothyronine) (Option D):** While T3 is the active hormone, it has a short half-life (approx. 24 hours), requiring multiple daily doses. It carries a higher risk of **cardiotoxicity** (palpitations, arrhythmias) due to rapid absorption and peak effects. It is primarily reserved for **Myxedema Coma** where a rapid onset is required. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** The best indicator of T4 efficacy is **Serum TSH** (measured after 6–8 weeks of therapy). * **Administration:** Should be taken on an **empty stomach** (30–60 mins before breakfast) as food, calcium, and iron supplements decrease its absorption. * **Pregnancy:** T4 requirements typically **increase** during pregnancy. * **Drug of choice for Myxedema Coma:** Intravenous **Liothyronine (T3)** or Levothyroxine (T4).

Question 126: Propylthiouracil is preferred over Methimazole in the treatment of thyroid storm because:

A. It is a more potent antithyroid drug.
B. It is less plasma protein bound.
C. It decreases the peripheral conversion of T4 to T3. (Correct Answer)
D. All of the above.

Explanation: **Explanation:** **1. Why Option C is Correct:** Thyroid storm is a life-threatening medical emergency characterized by an extreme hypermetabolic state. While both Propylthiouracil (PTU) and Methimazole inhibit the enzyme **thyroid peroxidase**, preventing the synthesis of new thyroid hormones, PTU has a unique additional mechanism. It inhibits the enzyme **5’-deiodinase**, which is responsible for the peripheral conversion of T4 (pro-hormone) to T3 (the more biologically active form). In a crisis, rapidly reducing the levels of active T3 is crucial, making PTU the preferred choice. **2. Why Other Options are Incorrect:** * **Option A:** Methimazole is actually **10 times more potent** than PTU. However, potency is less critical than the speed of action in an emergency. * **Option B:** PTU is **highly plasma protein-bound** (approx. 80-90%), whereas Methimazole has negligible protein binding. High protein binding in PTU is actually an advantage during pregnancy (1st trimester) as it crosses the placenta less readily. * **Option D:** Since A and B are factually incorrect, "All of the above" cannot be the answer. **Clinical Pearls for NEET-PG:** * **Pregnancy Rule:** PTU is preferred in the **1st trimester** (less teratogenic/lower risk of aplasia cutis). Methimazole is preferred in the **2nd and 3rd trimesters** (to avoid PTU-induced hepatotoxicity). * **Half-life:** Methimazole has a longer half-life, allowing for once-daily dosing, whereas PTU requires multiple doses. * **Side Effects:** Both can cause **agranulocytosis** (most serious) and skin rashes (most common). PTU carries a Black Box Warning for severe **hepatotoxicity**.

Question 127: Which antidiabetic drugs can be used safely in renal failure?

A. Glimepiride
B. Rosiglitazone
C. Repaglinide
D. All of these (Correct Answer)

Explanation: **Explanation:** The management of Diabetes Mellitus in patients with Chronic Kidney Disease (CKD) is challenging because many oral hypoglycemic agents (OHAs) are renally excreted and can accumulate, leading to severe hypoglycemia. The drugs listed in the options are notable exceptions or require specific considerations that make them safer in renal impairment. * **Repaglinide (Meglitinide):** This is considered one of the safest OHAs for renal failure. It has a very short half-life and is **primarily metabolized by the liver (90%)**, with less than 10% excreted by the kidneys. No dose adjustment is typically required even in advanced CKD. * **Rosiglitazone (Thiazolidinedione):** TZDs are extensively metabolized by the liver (CYP2C8). Their metabolites are excreted in the feces and urine, but the parent drug does not accumulate in renal failure. While they can cause fluid retention (caution in heart failure), they do not require dose adjustment for decreased GFR. * **Glimepiride (Sulfonylurea):** While most 1st and 2nd generation sulfonylureas (like Glyburide) are contraindicated in CKD due to active metabolites, **Glimepiride** is metabolized by the liver into inactive metabolites. Although it should be started at the lowest dose (1mg) and titrated cautiously, it is often used in mild-to-moderate renal impairment compared to other sulfonylureas. **Clinical Pearls for NEET-PG:** 1. **Drug of Choice (DOC):** Insulin remains the safest and most effective treatment for patients with ESRD. 2. **Linagliptin:** Among DPP-4 inhibitors, Linagliptin is the "unique" one as it is primarily excreted via the enterohepatic route and requires **no dose adjustment** in renal failure. 3. **Metformin:** Strictly contraindicated if eGFR < 30 mL/min due to the high risk of **Lactic Acidosis**. 4. **Vildagliptin:** Requires dose reduction in renal impairment (unlike Linagliptin).

Question 128: The anti-diabetic effect of sulfonylureas is primarily by reducing which of the following?

A. Glucagon production (Correct Answer)
B. Insulin secretion
C. Tissue sensitivity to insulin
D. Tissue sensitivity to glycogen

Explanation: ### Explanation **Correct Option: A. Glucagon production** Sulfonylureas (SUs) are insulin secretagogues that act on the pancreatic beta cells. While their immediate effect is to increase insulin release, their **chronic anti-diabetic effect** (the sustained lowering of blood glucose) is significantly attributed to the **reduction of serum glucagon levels**. This occurs via two mechanisms: 1. **Direct Inhibition:** SUs can directly inhibit alpha cells in the pancreas. 2. **Indirect Inhibition:** The increased intra-islet release of insulin and somatostatin (triggered by SUs) exerts a paracrine inhibitory effect on alpha cells, suppressing glucagon secretion. Lower glucagon levels lead to decreased hepatic glucose production, which is crucial for long-term glycemic control. **Analysis of Incorrect Options:** * **B. Insulin secretion:** Sulfonylureas **increase** insulin secretion by blocking ATP-sensitive K⁺ channels, leading to depolarization and calcium influx. Reducing insulin secretion would worsen diabetes. * **C. Tissue sensitivity to insulin:** This is the primary mechanism of **Biguanides (Metformin)** and **Thiazolidinediones (Pioglitazone)**. While SUs may have minor "extrapancreatic" effects on sensitivity, it is not their primary anti-diabetic mechanism. * **D. Tissue sensitivity to glycogen:** This is physiologically irrelevant in this context; glycogen is a storage form of glucose, not a signaling hormone like insulin. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Blockade of **SUR1** subunit of ATP-sensitive K⁺ channels in $\beta$-cells. * **Adverse Effects:** Hypoglycemia (most common) and weight gain. * **First-generation vs. Second-generation:** First-gen (e.g., Chlorpropamide) are rarely used due to long half-lives and disulfiram-like reactions. Second-gen (e.g., Glipizide, Gliclazide) are more potent. * **Safety:** **Gliclazide** is preferred in elderly patients due to a shorter half-life and lower risk of hypoglycemia. **Glimepiride** is considered "heart-friendly" as it has less effect on ischemic preconditioning in cardiac myocytes.

Question 129: Which of the following is a selective estrogen receptor modulator?

A. Centchroman (Correct Answer)
B. Mifepristone
C. Danazol
D. Anastrozole

Explanation: **Selective Estrogen Receptor Modulators (SERMs)** are compounds that exert tissue-specific effects, acting as estrogen agonists in some tissues (e.g., bone, liver) and antagonists in others (e.g., breast, endometrium). ### **Explanation of Options** * **A. Centchroman (Ormeloxifene):** This is the correct answer. It is a non-steroidal SERM developed in India (CDRI, Lucknow). It acts as an estrogen antagonist in the uterus and breast while maintaining a weak agonist effect elsewhere. It is primarily used as a **once-a-week oral contraceptive** (marketed as *Saheli* or *Chhaya*) and for dysfunctional uterine bleeding. * **B. Mifepristone:** This is a **Progesterone Receptor Antagonist** (and glucocorticoid antagonist). It is used for medical termination of pregnancy (MTP) and emergency contraception. * **C. Danazol:** This is an **ethisterone derivative** with weak androgenic activity. It inhibits gonadotropin secretion and is used in the treatment of endometriosis and hereditary angioedema. * **D. Anastrozole:** This is a **Selective Aromatase Inhibitor**. It prevents the peripheral conversion of androgens to estrogens and is a first-line treatment for postmenopausal breast cancer. ### **High-Yield NEET-PG Pearls** * **Centchroman's Mechanism:** It prevents implantation by altering the "receptive window" of the endometrium and increasing tubal motility. It does **not** suppress ovulation. * **Other SERMs to Remember:** * **Tamoxifen:** Antagonist in breast; Agonist in bone and **endometrium** (risk of endometrial cancer). * **Raloxifene:** Antagonist in breast and endometrium; Agonist in bone (used for postmenopausal osteoporosis). * **Clomiphene:** Antagonist in the hypothalamus; used for ovulation induction in infertility. * **Bazedoxifene:** A newer SERM used in combination with conjugated estrogens for menopausal symptoms.

Question 130: Aldosterone antagonists are not useful in the treatment of which of the following conditions?

A. Hypertension
B. Congestive heart failure
C. Gynaecomastia (Correct Answer)
D. Hirsutism

Explanation: **Explanation:** Aldosterone antagonists (Spironolactone and Eplerenone) are potassium-sparing diuretics that act by inhibiting the mineralocorticoid receptor [1]. **Why Gynaecomastia is the correct answer:** Aldosterone antagonists, specifically **Spironolactone**, are a **cause** of gynaecomastia, not a treatment for it [2]. Spironolactone is structurally similar to steroids and acts as a non-specific antagonist at androgen receptors while also increasing the peripheral conversion of testosterone to estradiol [4]. This hormonal imbalance leads to breast tissue enlargement in males (gynaecomastia) and erectile dysfunction as common side effects [2]. **Analysis of Incorrect Options:** * **Hypertension:** Aldosterone antagonists are used as add-on therapy in resistant hypertension to counteract the effects of sodium and water retention. * **Congestive Heart Failure (CHF):** They are "life-saving" drugs in CHF (NYHA Class II-IV). They prevent aldosterone-mediated cardiac remodeling and fibrosis, significantly reducing mortality. * **Hirsutism:** Due to its anti-androgenic properties (blocking androgen receptors and inhibiting steroidogenesis), Spironolactone is clinically used to treat hirsutism and acne in females [4]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Eplerenone** is a more selective mineralocorticoid antagonist; it has a lower affinity for androgen receptors and is therefore **less likely** to cause gynaecomastia compared to Spironolactone [2]. 2. **Hyperkalemia** is the most significant and life-threatening metabolic side effect of these drugs [3]. 3. **Drug of Choice:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and edema associated with **Liver Cirrhosis** (where secondary hyperaldosteronism is present) [3].

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free